Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:33 2025-01-14 am EST			5-day change	1st Jan Change
90.11 ^CHF	-0.75%		-0.31%	+1.59%

Jan. 13	Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	MT
Jan. 13	Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...

Novartis AG - Special Call

December 09, 2024 at 10:00 am EST

Presenter Speech
Maria Victoria Cuevas-Pautonnier (Executives)

Hello. Welcome to our Annual Impact and Sustainability Event. My name is Mavic Cuevas from the Novartis Investor Relations team, and I

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Novartis AG

Swiss Stocks Close Lower Ahead of Key Inflation, Economic Data	Jan. 13	MT
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	Jan. 13
Illumina Starts Pilot Program With Partners to Generate Proteomics Data	Jan. 13	MT
Novartis: Favourable court ruling on Entresto	Jan. 13	CF
Novartis's U.S. Patent for Entresto Upheld by Appeals Court	Jan. 13	DJ
US Court Upholds Validity of Novartis' Combination Patent for Entresto	Jan. 13	MT
Novartis Entresto(R) US patent upheld by US Court of Appeals	Jan. 13	DJ
NOVARTIS AG : Goldman Sachs remains Neutral	Jan. 09	ZD
Light Horse Therapeutics Inc announced that it expects to receive $87 million in funding from Versant Venture Management, LLC, Bristol-Myers Squibb Company, AbbVie Ventures, Inc., Taiho Ventures, LLC, Mubadala Capital, Novartis AG	Jan. 08	CI
NOVARTIS AG : Gets a Neutral rating from Berenberg	Jan. 07	ZD
NOVARTIS AG : Bernstein reiterates its Buy rating	Jan. 07	ZD
A poor 2024 increases the odds of a brighter 2025	Jan. 02
Experts expect more IPOs and takeovers in 2025	Jan. 02	RE
Swiss Stocks Close Higher Ahead of New Year Break	Dec. 30	MT
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint	Dec. 30	MT
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA	Dec. 30	DJ
Novartis Announces Positive Topline Results from the Phase III Steer Study	Dec. 30	CI
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	Dec. 27	MT
Sector Update: Health Care	Dec. 27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules	Dec. 27	MT
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules	Dec. 27	MT
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules	Dec. 27	RE
Novartis to Close MorphoSys Sites, Affecting 330 Jobs	Dec. 19	MT